Factors viii (A61K38/37)

Coagulation factor viii with reduced immunogenicity // 2631801
FIELD: biotechnology.SUBSTANCE: method comprises: (a) identification of at least one epitope of NKT cells, wherein the motif of the said NKT cell epitope is [FWTHY]-X2X3-[ILMV]-X5X6-[FWTHY], wherein at least one NKT cell epitope is in SEQ ID NO: 1 and (b) modification of the said epitope(s) by replacing at least one hydrophobic amino acid residue at position P1 and P7 with one amino acid other than F, W, T, H, Y.EFFECT: invention allows to obtain an active molecule of factor VIII, which has a reduced ability to activate NKT cells due to reduced binding to the CD1d molecule.6 cl, 6 dwg, 1 tbl, 7 ex
Treatment of coagulation disease by administration of recombinant vwf // 2628537
FIELD: medicine.SUBSTANCE: group of inventions relates to a method of treating von Willebrand's disease or hemophilia A in a patient in need of treatment comprising administering to the patient a recombinant vWF (vWF) factor so that the half-life of factor VIII is prolonged compared to a patient administered vWF derived from blood plasma, where pFB is not modified with an aqueous soluble polymer. In this case, the pFB is a composition of high molecular weight PV multimers containing at least 20% of the PV emperors or higher-order multimers, with the rVB having a higher specific activity than the vWF derived from the blood plasma. The group of inventions also relates to a method for treating hemophilia A or vWF in a patient in need of treatment that includes administering to the patient a recombinant vWF (vWF) factor, wherein the half-life of FVIII is at least 1.5 times higher than the half-life of FVIII in the patient being treated Von Willebrand factor derived from blood plasma.EFFECT: increase in the half-life of FVIII in the treatment of von Willebrand disease or haemophilia A in the subject.29 cl, 5 ex, 22 dwg, 34 tbl

Preparations containing von willebrand factor (vwf) and methods, kits and applications related to them // 2579977
FIELD: biotechnology.SUBSTANCE: shortened vWF variants are produced, connected with the Fc-part of immunoglobulin, capable to bind FVIII.EFFECT: invention enables to facilitate the production and purification of FVIII, contributes to prolongation of the half-life of FVIII in blood.12 cl, 11 dwg, 1 tbl, 3 ex

Conjugated factor viii molecules // 2573587
FIELD: chemistry.SUBSTANCE: invention relates to field of biotechnology, namely to obtaining B-domain truncated factor VIII molecule and covalently conjugated with hydrophilic polymer, which has altered half-life in bloodstream, and can be used in medicine to treat haemophilia. Molecule of precursor of B-domain truncated factor VII, where B-domain corresponds to amino acids 741-761 from SEQ ID NO 2, is obtained. Said molecule is covalently conjugated with PEG or polysaccharide with size 10-80 kDa by means of O-linked oligosaccharide at serine residue in truncated B-domain, which corresponds to amino acid 750 in SEQ ID NO 2.EFFECT: invention makes it possible to increase factor VIII half-life in bloodstream.8 cl, 8 dwg, 4 tbl, 7 ex

Von willebrand factor or factor viii and von willebrand factor for treatment of coagulopathy, induced by platelet inhibitors // 2563236
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to the field of pharmaceutics and medicine and deals with the application of the von Willebrand factor in a combination with factor VIII for the treatment and/or prevention of a haemorrhage episode, associated with thrombopathy, induced with platelet-inhibiting substances, the where platelet-inhibiting substance is represented by an inhibitor of ADP receptor or a combination of the inhibitor of FDP receptor and cyclooxygenase inhibitor. The invention also relates to a composition and a method of treatment and/or prevention of a disorder, associated with the haemorrhage, associated with thrombopathy, induced by the platelet-inhibiting substances.EFFECT: group of inventions provides the reduction or prevention of undesirable instances of the haemorrhage after the introduction of anticoagulants or fibrinolytics.19 cl, 6 dwg, 5 tbl, 2 ex

Human growth hormone derivative highly resistant to proteolytic degradation, method for preparing this derivative, using it, method of treating, and pharmaceutical composition // 2539797
FIELD: medicine.SUBSTANCE: invention refers to molecular biology, medicine, biochemistry and gene engineering. Presented is a human growth hormone derivative containing an additional disulphide bond as compared to hGh defined by SEQ ID No. 1, wherein the derivative contains at least one pair of mutations described by H21C/M170C, D26/V102C, D26/Y103C, F54C/Y143C, F54C/S144C, S55C/Y143C, S57C/Y143C, I58C/Q141C, I58C/Y143C, I58C/S144C, P59C/Q137C, S71C/S132C, L81C/Y143C, Q84C/Y143C, S85C/Y143C, S85C/S144C, F92C/T148C and/or R94C/D107C in SEQ ID No. 1, and possesses the activity of the human growth hormone, as well as a method for preparing this derivative, using it, a method of treating and a pharmaceutical composition.EFFECT: invention possesses high stability and resistance to proteolytic degradation as a consequence of the introduction of cysteine residues.18 cl, 3 dwg, 6 tbl, 5 ex

Recombinant factor viii, possessing higher stability // 2531493
FIELD: chemistry.SUBSTANCE: invention relates to the field of biochemistry, in particular to recombinant factor VIII, which contains one or more mutations, resulting in an increased stability of both the factor VIII and factor VIIIa, as well as to a pharmaceutical composition for treating haemophilia containing it. Also described is a molecule of nucleic acid, coding the said recombinant factor VIII, and an expression vector and host-cells, containing the said molecule of nucleic acid. The invention also relates to a method of obtaining the said factor VIII, as well as to its application in the method of treating haemophilia A in an animal.EFFECT: invention makes it possible to obtain a biologically active factor VIII with an increased stability.50 cl, 12 dwg, 5 tbl, 9 ex
New protective compositions for recombinant factor viii // 2510279
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to medicine, namely to pharmacology and describes a histidine-free pharmaceutical composition containing high-purity factor VIII; arginine and saccharose, a surfactant for the prevention or at least the inhibition of a surface adsorption of factor VIII; 0.5 to 10 mM calcium chloride for the specific stabilisation of factor VIII, and sodium citrate or maleic acid as a pH buffer.EFFECT: invention provides the protective function for preserve high-yield factor VIII over the whole cycle of pharmaceutical processing, long storage and end recovery and administration into the patient.18 cl, 16 tbl, 8 ex

Stabilisation of liquid solutions of recombinant protein for storing in frozen state // 2469739
FIELD: chemistry.SUBSTANCE: invention represents method of stabilisation of liquid solution of coagulation and/or clotting factors for storing in frozen state, which contains: providing liquid solution of coagulation and/or clotting factor, where said solution has concentration NaCl and/or KCl, at least, 100 mM; addition of carbohydrate to said solution until said solution reaches in freezing temperature of vitrifying -56°C or higher; and freezing of said solution for storage.EFFECT: invention ensures stabilisation of liquid solution of coagulation or clotting factors for storing in frozen state.20 cl, 1 tbl, 2 dwg

ethod for producing concentrated factor viii of human blood plasma // 2445974
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine and describes a method for recovery of factor VIII from human blood plasma not identified by related analysis of hepatitis and HIV1/2 viruses consisting in sequential cryoprecipitation, dissolution in an aqueous solution of heparin and solubilisation of a cryoprecipitate, sorption of a prothrombin-converting complex factor by aluminium hydrate, removal of fibrinogen, fibronectin and associated protein by polyethylene glycol-4000, viral inactivation with solvent detergents and preliminary filtration, anion-exchange chromatography, preferentially with EDM-TMAE Fractogel, with elution by a sodium chloride buffer, stabilisation by albumine solution, sterile filtration in membrane filters of pore diameter 0.22 mcm, bottling (200-300 IU/bottle), lyophilisation and second thermal viral inactivation with purification using the aqueous solution of unfractionated heparin of the concentrations equal to 5-100 international units (IU)/ml, preferentially 10-25 IU/ml, polyethylene glycol-4000 in the final concentration 3.5% and acidification of the medium, preferentially to pH 6.6, strong TMAE anion exchangers.EFFECT: method substantially provides higher effectiveness of purification and specific activity of factor VIII.1 tbl, 4 dwg, 2 ex

Fviii modification trend site // 2423380
FIELD: medicine, pharmaceutics.SUBSTANCE: invention concerns area of molecular biology and biochemistry, and can be used in medicine. There is offered mutein conjugate of the blood coagulation factor VIII (FVIII) wherein a residue not being cysteine in position 41, 129, 377, 388, 468, 491, 556, 1804, 1808, 1810, 1812, 1813, 1815 and/or 2118 is substituted by a cysteine residue with polyethylene glycol (PEG) where a PEG molecule is bound with a polypeptide in a mutant cysteine residue.EFFECT: improved pharmacokinetic properties of the FVIII as an ingredient of the conjugate under the invention with preserved a procoagulant factor activity allows presenting new FVIII PEG-muteins for producing of a pharmaceutical compositions for treating hemophilia.12 cl, 38 dwg, 8 tbl, 1 ex

ethod for producing concentrated von willebrand factor or factor viii/von willebrand factor complex and applying thereof // 2417096
FIELD: medicine, pharmaceutics.SUBSTANCE: declared invention refers to chemical-pharmaceutical industry. A method involves the following stages: preparing a solution of von Willebrand factor or von Willebrand factor/factor VIII complex which contains VWF in concentration up to 12 IU VWF:RCoAui and has the von Willebrand factor/factor VIII ratio equal to 0.4 or more; nanofiltering through a filter of pore size less than 35 nanometres at pressure less than or equal to 0.5 bar and in the presence of 0.05 to 0.2 M of calcium ions.EFFECT: development of the effective method for producing concentrated von Willebrand factor or factor VIII/von Willebrand factor complex to be applied for treating hemophilia And or von Willebrand disease.11 cl, 8 ex, 6 tbl, 1 dwg

Isolated glycoprotein ib alpha polypeptide of human thrombocytes, fused protein, dna molecule (versions), expression vector (versions), cell (versions), polypeptide expression method, fused protein expression method, pharmaceutical composition (versions), method of inhibiting boding of blood cells to biological tissue in biological system, method of inhibiting bonding of protein to biological tissue in biological system and disorder treatment method // 2403262
FIELD: chemistry; biochemistry.SUBSTANCE: invention relates to biotechnology and specifically to obtaining versions of glycoprotein IV alpha polypeptide of human thrombocytes (GPIbalpha) and can be used in medicine to treat vascular disorders. Using a recombinant technique, a polypeptide is obtained, which contains substitutes in SEQ ID NO:2 selected from: Y276F K237V C65S; K237V C65S; Y276F C65S; or Y276F Y278F Y279F K237V C65S. The obtained polypeptide is used to inhibit bonding of leucocytes to biological tissue or for treating disorders associated with activation of thrombocytes.EFFECT: invention enables to obtain GPIbalpha polypeptide which bonds with von Willebrand factor with affinity which is at least 10 times higher than in natural GPIbα polypeptide, and also has low affinity for bonding with alpha-thrombin, lower aggregation and/or high resistance to proteolysis relative the polypeptide with SEQ ID NO:2.41 cl, 3 dwg, 8 ex

Compositions and methods of mammary gland cancer therapy and diagnostics // 2344831
FIELD: medicine.SUBSTANCE: invention claims compositions which can include one or several mammary gland tumour proteins, their immunogenic parts or polynucleotides encoding such parts. Alternatively the therapeutic composition can include antigen-presenting cell expressing mammary gland tumour protein, or T-cell specific to cells expressing such protein. These compositions can be applied in prevention and treatment of such diseases as mammary gland cancer. Invention also claims diagnostic methods based on determination of mammary gland tumour protein or mRNA encoding such protein in sample.EFFECT: use of peptides obtained from protein expressed from mammary gland by tumour in diagnostics and therapy of mammary gland cancer.37 cl, 6 ex, 1 dwg
ethod of human blood coagulation viii factor concentrate production and related product // 2326689
FIELD: medicine; pharmacology.SUBSTANCE: invention refers to method of human blood coagulation VIII factor production and related product. Method includes blood serum as cryoprecipitate, heparine added, PEG-4000, centrifugation, supernatant is added with tributyl phosphate and Twin-80, repeated centrifugation, sediment washed with sodium chloride, then it is dissolved in tris-HCl buffer with additives, let through column filled with gel and attached antibodies to Willebrand's factor, factor VIII elution, dialysis. Produced concentrate does not contain Willebrand's factor and has activity not less than 300 ME/mg of protein with purity not less 98% and contains albumin of concentration of 0.1%. Product is lyophilized with further processing.EFFECT: product does not display any toxicity and cause allergic reaction.6 cl, 2 ex
ethod of making preparation of human blood coagulaton factor viii // 2324495
FIELD: technological processes.SUBSTANCE: preparation of human blood coagulation factor VIII is made by producing cryoprecipitate out of blood plasma, virus inactivating treatment, purification of cryoprecipitate solution, concentration, sterilizing filtration, bottling and drying. At the same time cryoprecipitate is produced with the help of running water with the temperature of (4±2)°C during unfreezing of fresh frozen plasma, virus inactivating treatment is carried out by means of solvent-detergent method, chromatographic purification of virus inactivated cryoprecipitate solution is carried out with application of sorbent with fractionation interval up to 20,000 kilodaltons, at the flow rate of (20±15) cm/hr, with further concentration by means of ultrafiltration on hollow fibers. Stabilizers are added, such as albumin in final concentration of (5±3) g/l, sugars and amino acids up to final concentration of (10±3) g/l. During drying initial preparation temperature is (25±15)°C below zero, final temperature is (25±8)°C, total duration of preparation drying process is (45±7) hours.EFFECT: coagulation factor yield stability is increased and technological production design is simplified.2 ex

Stable pharmaceutical composition containing viii factor // 2314825
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to a novel stable ready formulation of pharmaceutical composition containing VIII factor and can be used in treatment of hemophilia. Invention relates to a solid pharmaceutical composition prepared by lyophilization of an amino acid-free solution and comprising the following components: (a) VIII factor in the concentration 50-10000 IU/ml for human VIII factor or human recombinant VIII factor, or 50-10000 U/ml for swine VIII factor or swine recombinant VIII factor; (b) surfactant in the concentration above critical micellar concentration up to 1% (vol./vol.); (c) calcium chloride; (d) sucrose; (e) sodium chloride; (f) trisodium citrate, and (g) amino acids-free buffer in the concentration 1-50 mM with pH 6-8 before lyophilization and after dissolving in water for injection. Also, invention relates to a liquid pharmaceutical composition prepared after dissolving indicated stable solid pharmaceutical composition in sterile water optionally containing sodium chloride. Invention provides preparing a stable ready formulation of pharmaceutical composition of VIII factor wherein albumin is replaced with other stabilizing agents.EFFECT: improved and valuable properties of pharmaceutical composition.25 cl, 3 tbl, 3 ex

Combined application of factor vii polypeptides and factor viii polypeptides // 2311923
FIELD: medicine, pharmaceuticals.SUBSTANCE: invention relates to pharmaceutical agent containing factor VII or factor VII-related polypeptide and factor VIII or factor VIII-related polypeptide. Disclosed are application of factor VII or factor VII-related polypeptide and factor VIII or factor VIII-related polypeptide in production of drug, kit for episodic bleeding treatment, as well as methods for prophylaxis and treatment of episodic bleeding in subject.EFFECT: accelerated coagulation of FVIII-deficit plasma.43 cl, 1 tbl, 2 dwg, 6 ex
ethod for enriching donor blood plasma cryoprecipitate with factor viii // 2293570
FIELD: medicine.SUBSTANCE: invention relates to methods for preparing biologically active substances from donor blood. Method for enriching donor blood plasma cryoprecipitate with factor VIII involves defrosting freshly frozen donor blood plasma at +1-4°C to obtain cryofractions from plasma cryosupernatant and cryoprecipitate. After formation of the donor blood freshly frozen plasma dry calcium chloride is added in the amount from 0.001 to 0.004 mole/l followed by addition of sodium citrate in the amount from 0.05 to 0.10 mole/l and stirring at +1-4°C for 10-15 min. Then prepared cryoprecipitate deposit is separated by centrifugation. For preparing cryoprecipitate freshly frozen plasma is used prepared by usual method with using conventional preserving agents. Using the method provides significant increasing the content of factor VIII in cryoprecipitate being without appreciable co-precipitation of inert proteins.EFFECT: improved enriching method.2 tbl, 3 ex
ethod of preparing factor viii preparation // 2253475
FIELD: pharmaceutical industry and biotechnology.SUBSTANCE: method consists in the following: kryoprecipitate of donor blood plasma is suspended in heparin solution, resulting suspension is consecutively treated with aluminum hydroxide and polyethylene glycol-400 to remove ballast proteins until content of aluminum hydroxide in solution achieves 0.3% and that of polyethylene glycol-400 2%. Thus treated material is subjected to viral inactivation by solvent-detergent technique in presence of Tween and microfiltration followed by chromatographic fractionation on DEAE-containing carrier using buffer solutions, pH 6.75-6.85, with different ionic forces. Resulting concentrate of factor VIII is stabilized with albumin solution to provide final albumin concentration in the preparation 0.1%, sterilized by microfiltration, and transferred into lyophilized form, in which viruses are additionally inactivated via heat treatment.EFFECT: preserved specific activity of factor VIII with high degree of purification and increased storage stability.5 cl, 1 tbl
New albumin-free compositions of factor viii // 2244556
FIELD: medicine, hematology, pharmacy.SUBSTANCE: invention relates to the composition of factor VIII composed without addition of albumin and comprising the following excipients of composition in addition to factor VIII: from 4% to 10% of filling agent taken among group consisting of mannitol, glycine and alanine; from 1% to 4% of stabilizing agent taken among group consisting of sucrose, trehalose, raffinose, arginine; from 1 mM to 5 mM of calcium salt, from 100 mM to 300 mM of NaCl, and buffer agent for pH value maintenance about between 6 and 8. Alternatively, the composition can comprise from 2% to 6% of hydroxyethylstarch; from 1% to 4% of stabilizing agent taken among group consisting of sucrose, trehalose, raffinose, arginine; from 1 mM to 5 mM of calcium salt, from 100 mM to 300 mM of NaCl, and buffer agent for pH value maintenance between 6 and 8. In additional variant of realization of invention the composition can comprise: from 300 mM to 500 mM of NaCl, from 1% to 4% of stabilizing agent taken among group consisting of sucrose, trehalose, raffinose and arginine; from 1 mM to 5 mM of calcium salt, and buffer agent. The composition provides stability in the absence of albumin or other proteins.EFFECT: valuable properties of compositions.35 cl, 11 tbl, 7 ex
Biological adhesive glue // 2224540
The invention relates to the field of medicine and relates to adhesive compositions to stop bleeding on the basis of factor VIII

Stable, free from albumin liofilizovannye composition of recombinant factor viii // 2201252
The invention relates to medicine and sustainable, not containing albumin preparation of recombinant Factor VIII (rFVIII) in dried form, which has both crystalline and amorphous components, which after dilution water contains from about 65 to 400 mm glycine, 50 mm histidine, from 15 to 60 mm sucrose, 1 to 50 mm sodium chloride, 5 mm calcium chloride and from 50 to 1500 IU/ml rFVIII
ethod of sealing a puncture channel after diagnostic endoscopic biopsy of the liver in patients with hemophilia and // 2200028
The invention relates to medicine, in particular to Hematology, and can be used for sealing a puncture channel after diagnostic endoscopic biopsy of the liver in patients with hemophilia And
The method of obtaining, using chromatographic methods of virus-inactivated fraction containing factor viii // 2148411
The invention relates to medicine, in particular to Hematology

An aqueous solution of factor viii with reduced oxygen concentration // 2142290
The invention relates to medicine, namely to the pharmacy, and relates to a product comprising coagulation factor VIII in aqueous solution with reduced oxygen concentration

The composition containing the product of coagulation factor viii, its preparation and application of surfactants as stabilizer // 2136294
The invention relates to medicine and can be used to treat patients suffering from hemophilia